FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Christoph Huber

Research Profile

Chemicals & Drugs

Anatomy

Disorders

Living Beings

Mouse

Physiology

Procedures

Transplantation, Homologous

Co-author Network

Publications

TOP 3
John C Castle; Jos de Graaf; Jan Diekmann; Mustafa Diken; Christoph Huber; Michael Koslowski; Sebastian Kreiter; Andreas N Kuhn; Martin Löwer; Claudia Paret; Sebastian Boegel; Cedrik Michael Britten; Abderraouf Selmi; Ozlem Türeci; Niels van de Roemer; Ugur Sahin
Exploiting the mutanome for tumor vaccination.
Sebastian Kreiter; Abderraouf Selmi; Ozlem Türeci; Sebastian Attig; Jan Diekmann; Mustafa Diken; Christoph Huber; Yves Hüsemann; Michael Koslowski; Ugur Sahin
FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.
M Diken; Christoph Huber; Sebastian Kreiter; A Selmi; Ozlem Türeci; Cedrik Michael Britten; Ugur Sahin
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Christoph Huber (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2012: John C Castle; Jos de Graaf; Jan Diekmann; Mustafa Diken; Christoph Huber; Michael Koslowski; Sebastian Kreiter; Andreas N Kuhn; Martin Löwer; Claudia Paret; Sebastian Boegel; Cedrik Michael Britten; Abderraouf Selmi; Ozlem Türeci; Niels van de Roemer; Ugur Sahin
Exploiting the mutanome for tumor vaccination.
Cancer research 2012;72(5):1081-91.
2011: Sebastian Kreiter; Abderraouf Selmi; Ozlem Türeci; Sebastian Attig; Jan Diekmann; Mustafa Diken; Christoph Huber; Yves Hüsemann; Michael Koslowski; Ugur Sahin
FLT3 ligand enhances the cancer therapeutic potency of naked RNA vaccines.
Cancer research 2011;71(19):6132-42.
2011: M Diken; Christoph Huber; Sebastian Kreiter; A Selmi; Ozlem Türeci; Cedrik Michael Britten; Ugur Sahin
Selective uptake of naked vaccine RNA by dendritic cells is driven by macropinocytosis and abrogated upon DC maturation.
Gene therapy 2011;18(7):702-8.
2011: Cedrik Michael Britten; S Janetzki; Sjoerd H van der burg; Christoph Huber; M Kalos; Hyam I Levitsky; Holden T Maecker; C J M Melief; J O'Donnell-Tormey; K Odunsi; L J Old; Graham Pawelec; B O Roep; P Romero; A Hoos; M M Davis
Minimal information about T cell assays: the process of reaching the community of T cell immunologists in cancer and beyond.
Cancer immunology, immunotherapy : CII 2011;60(1):15-22.
2010: Sebastian Kreiter; Abderraouf Selmi; Mustafa Diken; Michael Koslowski; Cedrik M Britten; Christoph Huber; Ozlem Türeci; Ugur Sahin
Intranodal vaccination with naked antigen-encoding RNA elicits potent prophylactic and therapeutic antitumoral immunity.
Cancer research 2010;70(22):9031-40.
2010: A N Kuhn; M Diken; Sebastian Kreiter; A Selmi; J Kowalska; J Jemielity; E Darzynkiewicz; Christoph Huber; Ozlem Türeci; Ugur Sahin
Phosphorothioate cap analogs increase stability and translational efficiency of RNA vaccines in immature dendritic cells and induce superior immune responses in vivo.
Gene therapy 2010;17(8):961-71.
2010: Ralf G Meyer; E M Wagner; Abdo Konur; Klaus Bender; T Schmitt; J Hemmerling; D Wehler; Udo Hartwig; E Roosnek; Christoph Huber; Karin Kolbe; Wolfgang Herr
Donor CD4 T cells convert mixed to full donor T-cell chimerism and replenish the CD52-positive T-cell pool after alemtuzumab-based T-cell-depleted allo-transplantation.
Bone marrow transplantation 2010;45(4):668-74.
2010: B Markova; C Albers; F Breitenbuecher; J V Melo; T H Brümmendorf; Florian Heidel; D Lipka; J Duyster; Christoph Huber; Thomas Fischer
Novel pathway in Bcr-Abl signal transduction involves Akt-independent, PLC-gamma1-driven activation of mTOR/p70S6-kinase pathway.
Oncogene 2010;29(5):739-51.
2009: Michael Koslowski; Ozlem Türeci; Stefan Biesterfeld; Gerhard Seitz; Christoph Huber; Ugur Sahin
Selective activation of trophoblast-specific PLAC1 in breast cancer by CCAAT/enhancer-binding protein beta (C/EBPbeta) isoform 2.
The Journal of biological chemistry 2009;284(42):28607-15.
2009: Vladimir Chobot; Christoph Huber; Guenter Trettenhahn; Franz Hadacek
(+/-)-catechin: chemical weapon, antioxidant, or stress regulator?
Journal of chemical ecology 2009;35(8):980-96.
2009: Frank Breitenbuecher; Boyka Markova; Stefan Kasper; Birgit Carius; Torsten Stauder; Frank D Böhmer; Kristina Masson; Lars Rönnstrand; Christoph Huber; Thomas Kindler; Thomas Fischer
A novel molecular mechanism of primary resistance to FLT3-kinase inhibitors in AML.
Blood 2009;113(17):4063-73.
2009: Frank Breitenbuecher; Susanne Schnittger; Rebekka Grundler; Boyka Markova; Birgit Carius; Alexandra Brecht; Justus Duyster; Torsten Haferlach; Christoph Huber; Thomas Fischer
Identification of a novel type of ITD mutations located in nonjuxtamembrane domains of the FLT3 tyrosine kinase receptor.
Blood 2009;113(17):4074-7.
2009: Michael Koslowski; Ozlem Türeci; Christoph Huber; Ugur Sahin
Selective activation of tumor growth-promoting Ca2+ channel MS4A12 in colon cancer by caudal type homeobox transcription factor CDX2.
Molecular cancer 2009;8():77.
2008: Ugur Sahin; Michael Koslowski; Karl Dhaene; Dirk Usener; Gunda Brandenburg; Gerhard Seitz; Christoph Huber; Ozlem Türeci
Claudin-18 splice variant 2 is a pan-cancer target suitable for therapeutic antibody development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(23):7624-34.
2008: Eva Distler; Elke Schnürer; Eva Wagner; Charis von Auer; Bodo Plachter; Daniela Wehler; Christoph Huber; Karin Kolbe; Ralf G Meyer; Wolfgang Herr
Recovery of varicella-zoster virus-specific T cell immunity after T cell-depleted allogeneic transplantation requires symptomatic virus reactivation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(12):1417-24.
2008: Thomas Wehler; Michael Karg; Eva Distler; Abdo Konur; Marion Nonn; Ralf G Meyer; Christoph Huber; Udo Hartwig; Wolfgang Herr
Rapid identification and sorting of viable virus-reactive CD4(+) and CD8(+) T cells based on antigen-triggered CD137 expression.
Journal of immunological methods 2008;339(1):23-37.
2008: Marion Nonn; Wolfgang Herr; Shamsul Khan; Mariya Todorova; Irina Link; Jochen Thies; Eva Distler; Marcus Kaltwasser; Julia Hoffmann; Christoph Huber; Udo Hartwig
Selective depletion of alloreactive T lymphocytes using patient-derived nonhematopoietic stimulator cells in allograft engineering.
Transplantation 2008;86(10):1427-35.
2008: Marcus Schuchmann; Ralf G Meyer; E Distler; Esther Von Stebut; Jürgen Kuball; Elke Schnürer; T Wölfel; M Theobald; Abdo Konur; S Gregor; O Schreiner; Christoph Huber; Peter R Galle; Gerd Otto; Wolfgang Herr
The programmed death (PD)-1/PD-ligand 1 pathway regulates graft-versus-host-reactive CD8 T cells after liver transplantation.
American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2008;8(11):2434-44.
2008: Stefan Kasper; Frank Breitenbuecher; Yvette Hoehn; Florian Heidel; Daniel B Lipka; Boyka Markova; Christoph Huber; Thomas Kindler; Thomas Fischer
The kinase inhibitor LS104 induces apoptosis, enhances cytotoxic effects of chemotherapeutic drugs and is targeting the receptor tyrosine kinase FLT3 in acute myeloid leukemia.
Leukemia research 2008;32(11):1698-708.
2008: S Tschiedel; Chiara Gentilini; Thoralf Lange; C Wölfel; T Wölfel; V Lennerz; S Stevanovic; H-G Rammensee; Christoph Huber; Michael Cross; Dietger Niederwieser
Identification of NM23-H2 as a tumour-associated antigen in chronic myeloid leukaemia.
Leukemia 2008;22(8):1542-50.
2008: Catherine Wölfel; Volker Lennerz; Eva Lindemann; Georg Hess; Hans Günter Derigs; Christoph Huber; Wolfgang Herr; Thomas Wölfel
Dissection and molecular analysis of alloreactive CD8+ T cell responses in allogeneic haematopoietic stem cell transplantation.
Cancer immunology, immunotherapy : CII 2008;57(6):849-57.
2008: Daniel B Lipka; Linda S Hoffmann; Florian Heidel; Boyka Markova; Marie-Christine Blum; Frank Breitenbuecher; Stefan Kasper; Thomas Kindler; Ross Levine; Christoph Huber; Thomas Fischer
LS104, a non-ATP-competitive small-molecule inhibitor of JAK2, is potently inducing apoptosis in JAK2V617F-positive cells.
Molecular cancer therapeutics 2008;7(5):1176-84.
2008: Michael Koslowski; Ugur Sahin; Karl Dhaene; Christoph Huber; Ozlem Türeci
MS4A12 is a colon-selective store-operated calcium channel promoting malignant cell processes.
Cancer research 2008;68(9):3458-66.
2008: Eva Distler; Catherine Wölfel; Sylvia Köhler; Marion Nonn; Nina Kaus; Elke Schnürer; Ralf G Meyer; Thomas Wehler; Christoph Huber; Thomas Wölfel; Udo Hartwig; Wolfgang Herr
Acute myeloid leukemia (AML)-reactive cytotoxic T lymphocyte clones rapidly expanded from CD8(+) CD62L((high)+) T cells of healthy donors prevent AML engraftment in NOD/SCID IL2Rgamma(null) mice.
Experimental hematology 2008;36(4):451-63.
2008: Georg Hess; Ralf G Meyer; Brigitte Schuch; Katja Bechthold; Ilse El-Kholy; Christoph Huber
Sustained remissions and low rate of BCR-ABL resistance mutations with imatinib treatment chronic myelogenous leukemia in patients treated in late chronic phase: a 5-year follow up.
American journal of hematology 2008;83(3):178-84.
2008: Cedrik Michael Britten; Cécile Gouttefangeas; Marij J P Welters; Graham Pawelec; Sven Koch; C Ottensmeier; A Mander; S Walter; Annette Paschen; Jan Muller-Berghaus; I Haas; Andreas Mackensen; Tania Køllgaard; Per thor Straten; M Schmitt; K Giannopoulos; R Maier; Hendrik Veelken; Cristina Bertinetti; Abdo Konur; Christoph Huber; S Stevanović; Thomas Wölfel; Sjoerd H van der burg
The CIMT-monitoring panel: a two-step approach to harmonize the enumeration of antigen-specific CD8+ T lymphocytes by structural and functional assays.
Cancer immunology, immunotherapy : CII 2008;57(3):289-302.
2008: Celio A Marques; Patricia S Hähnel; Catherine Wölfel; Sonja Thaler; Christoph Huber; Matthias Theobald; Martin Schuler
An immune escape screen reveals Cdc42 as regulator of cancer susceptibility to lymphocyte-mediated tumor suppression.
Blood 2008;111(3):1413-9.
2008: Daniel Lipka; Florian Heidel; Christoph Huber; Thomas Fischer
[Development of tyrosine kinase inhibitors for hematologic neoplasms. FLT3 and JAK2 as therapeutic targets].
Pharmazie in unserer Zeit 2008;37(5):394-403.
2008: Udo Hartwig; Marion Nonn; Shamsul Khan; Irina Link; Christoph Huber; Wolfgang Herr
Depletion of alloreactive donor T lymphocytes by CD95-mediated activation-induced cell death retains antileukemic, antiviral, and immunoregulatory T cell immunity.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 2008;14(1):99-109.
2008: Ralf-Holger Voss; Ralph A Willemsen; Jürgen Kuball; Margarete Grabowski; Renate Engel; Ratna S Intan; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Molecular design of the Calphabeta interface favors specific pairing of introduced TCRalphabeta in human T cells.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(1):391-401.
2008: Sebastian Kreiter; Abderraouf Selmi; Mustafa Diken; Martin Sebastian; Phillip Osterloh; Hansjörg Schild; Christoph Huber; Ozlem Türeci; Ugur Sahin
Increased antigen presentation efficiency by coupling antigens to MHC class I trafficking signals.
Journal of immunology (Baltimore, Md. : 1950) 2008;180(1):309-18.
2007: Emmanuelle Wesarg; Sandra Hoffarth; Rainer Wiewrodt; Monika Kröll; Stefan Biesterfeld; Christoph Huber; Martin Schuler
Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
International journal of cancer. Journal international du cancer 2007;121(11):2387-94.
2007: Stefan Kasper; Thomas Kindler; Sebastian Sonnenschein; Frank Breitenbuecher; Frank D Böhmer; Christoph Huber; Thomas Fischer
Cross-inhibition of interferon-induced signals by GM-CSF through a block in Stat1 activation.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2007;27(11):947-59.
2007: Michael Koslowski; Ugur Sahin; Rita Mitnacht-Kraus; Gerhard Seitz; Christoph Huber; Ozlem Türeci
A placenta-specific gene ectopically activated in many human cancers is essentially involved in malignant cell processes.
Cancer research 2007;67(19):9528-34.
2007: Ralf G Meyer; Stephanie Korn; Patrick Micke; Kai Becker; Christoph Huber; Thomas Wölfel; Roland Buhl
An open-label, prospective phase I/II study evaluating the immunogenicity and safety of a ras peptide vaccine plus GM-CSF in patients with non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2007;58(1):88-94.
2007: Sebastian Kreiter; Thorsten Konrad; Martina Sester; Christoph Huber; Ozlem Türeci; Ugur Sahin
Simultaneous ex vivo quantification of antigen-specific CD4+ and CD8+ T cell responses using in vitro transcribed RNA.
Cancer immunology, immunotherapy : CII 2007;56(10):1577-87.
2007: Stefan Kasper; Markus F Neurath; Christoph Huber; Matthias Theobald; Inge Scharrer
Protein A immunoadsorption therapy for refractory, mitomycin C-associated thrombotic microangiopathy.
Transfusion 2007;47(7):1263-7.
2007: Ralf G Meyer; Claudine Graf; Cedrik Michael Britten; Christoph Huber; Thomas Wölfel
Rapid identification of an HLA-B*1501-restricted vaccinia peptide antigen.
Vaccine 2007;25(24):4715-22.
2007: Claudine Graf; Florian Heidel; Stefan Tenzer; Markus P Radsak; Fian K Solem; Cedrik Michael Britten; Christoph Huber; Thomas Fischer; Thomas Wölfel
A neoepitope generated by an FLT3 internal tandem duplication (FLT3-ITD) is recognized by leukemia-reactive autologous CD8+ T cells.
Blood 2007;109(7):2985-8.
2007: Florian Heidel; Jorge Cortes; Frank G Rücker; Walter Aulitzky; Laurie Letvak; Thomas Kindler; Christoph Huber; Hartmut Döhner; Andrew Lamb; Thomas Fischer
Results of a multicenter phase II trial for older patients with c-Kit-positive acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR-MDS) using low-dose Ara-C and Imatinib.
Cancer 2007;109(5):907-14.
2007: Florian Heidel; Daniel B Lipka; Charis von Auer; Christoph Huber; Inge Scharrer; Georg Hess
Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.
Thrombosis and haemostasis 2007;97(2):228-33.
2007: Ralf G Meyer; Cedrik Michael Britten; Daniela Wehler; Klaus Bender; Georg Hess; Abdo Konur; Udo Hartwig; Thomas Wehler; Andrew J Ullmann; Chiara Gentilini; Lutz Uharek; Christoph Huber; Karin Kolbe; Wolfgang Herr
Prophylactic transfer of CD8-depleted donor lymphocytes after T-cell-depleted reduced-intensity transplantation.
Blood 2007;109(1):374-82.
2007: Thomas Wehler; Marion Nonn; Britta Brandt; Cedrik Michael Britten; Mark Gröne; Mariya Todorova; Irina Link; Shamsul A Khan; Ralf G Meyer; Christoph Huber; Udo Hartwig; Wolfgang Herr
Targeting the activation-induced antigen CD137 can selectively deplete alloreactive T cells from antileukemic and antitumor donor T-cell lines.
Blood 2007;109(1):365-73.
2006: Silke Holtkamp; Sebastian Kreiter; Abderraouf Selmi; Petra Simon; Michael Koslowski; Christoph Huber; Ozlem Türeci; Ugur Sahin
Modification of antigen-encoding RNA increases stability, translational efficacy, and T-cell stimulatory capacity of dendritic cells.
Blood 2006;108(13):4009-17.
2006: Sandra Kausche; Thomas Wehler; Elke Schnürer; Volker Lennerz; Walburgis Brenner; Sebastian W Melchior; Mark Gröne; Marion Nonn; Susanne Strand; Ralf Meyer; Elena Ranieri; Christoph Huber; Christine S Falk; Wolfgang Herr
Superior antitumor in vitro responses of allogeneic matched sibling compared with autologous patient CD8+ T cells.
Cancer research 2006;66(23):11447-54.
2006: Georg Hess; Thomas Flohr; Karin Kolbe; Sarah Bonn; Martin Schuler; Hans Günter Derigs; Christoph Huber
Effect of rituximab on the long-term outcome after high-dose therapy for relapsed B-cell non-Hodgkin's lymphoma.
Annals of hematology 2006;85(11):769-79.
2006: Michael Koslowski; Ugur Sahin; Christoph Huber; Ozlem Türeci
The human X chromosome is enriched for germline genes expressed in premeiotic germ cells of both sexes.
Human molecular genetics 2006;15(15):2392-9.
2006: Carolin Grunwald; Michael Koslowski; Tülin Arsiray; Karl Dhaene; Marleen Praet; Anja Victor; Alicia Morresi-Hauf; Michael Lindner; Bernward Passlick; Hans-Anton Lehr; Stephan C Schäfer; Gerhard Seitz; Christoph Huber; Ugur Sahin; Ozlem Türeci
Expression of multiple epigenetically regulated cancer/germline genes in nonsmall cell lung cancer.
International journal of cancer. Journal international du cancer 2006;118(10):2522-8.
2006: Udo Hartwig; Marion Nonn; S Khan; Ralf G Meyer; Christoph Huber; Wolfgang Herr
Depletion of alloreactive T cells via CD69: implications on antiviral, antileukemic and immunoregulatory T lymphocytes.
Bone marrow transplantation 2006;37(3):297-305.
2006: Jörg Chromik; Elke Schnürer; Ralf Georg Meyer; Thomas Wehler; Thomas Tüting; Thomas Wölfel; Christoph Huber; Wolfgang Herr
Proteasome-inhibited dendritic cells demonstrate improved presentation of exogenous synthetic and natural HLA-class I peptide epitopes.
Journal of immunological methods 2006;308(1-2):77-89.
2006: Ralf-Holger Voss; Jürgen Kuball; Renate Engel; Philippe Guillaume; Pedro Romero; Christoph Huber; Matthias Theobald
Redirection of T cells by delivering a transgenic mouse-derived MDM2 tumor antigen-specific TCR and its humanized derivative is governed by the CD8 coreceptor and affects natural human TCR expression.
Immunologic research 2006;34(1):67-87.
2006: Florian Heidel; Fian K Solem; Frank Breitenbuecher; Daniel B Lipka; Stefan Kasper; M H Thiede; Christian Brandts; Hubert Serve; Johannes Roesel; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary J Schiller; Stephen D Nimer; Richard M Stone; Yanfeng Wang; Thomas Kindler; Pamela S Cohen; Christoph Huber; Thomas Fischer
Clinical resistance to the kinase inhibitor PKC412 in acute myeloid leukemia by mutation of Asn-676 in the FLT3 tyrosine kinase domain.
Blood 2006;107(1):293-300.
2005: Sandra Hofmann; Matthias Glückmann; Sandra Kausche; Andrea Schmidt; Carsten Corvey; Rudolf Lichtenfels; Christoph Huber; Christian Albrecht; Michael Karas; Wolfgang Herr
Rapid and sensitive identification of major histocompatibility complex class I-associated tumor peptides by Nano-LC MALDI MS/MS.
Molecular & cellular proteomics : MCP 2005;4(12):1888-97.
2005: Volker Lennerz; Martina Fatho; Chiara Gentilini; Roy A Frye; Alexander Lifke; Dorothea Ferel; Catherine Wölfel; Christoph Huber; Thomas Wölfel
The response of autologous T cells to a human melanoma is dominated by mutated neoantigens.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(44):16013-8.
2005: Georg Hess; Donald Bunjes; Wolfgang Siegert; Rainer Schwerdtfeger; Georg Ledderose; Barbara Wassmann; Guido Kobbe; Martin Bornhäuser; Andreas Hochhaus; Andrew J Ullmann; Thomas Kindler; Ulrike Haus; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(30):7583-93.
2005: Carina Lotz; Sarah Abdel Mutallib; Nicole Oehlrich; Ulrike Liewer; Edite Antunes Ferreira; Marion Moos; Michael Hundemer; Sandra Schneider; Susanne Strand; Christoph Huber; Hartmut Goldschmidt; Matthias Theobald
Targeting positive regulatory domain I-binding factor 1 and X box-binding protein 1 transcription factors by multiple myeloma-reactive CTL.
Journal of immunology (Baltimore, Md. : 1950) 2005;175(2):1301-9.
2005: Udo Hartwig; Nils Winkelmann; Thomas Wehler; Sebastian Kreiter; Peter M Schneider; Ralf G Meyer; Andrew J Ullmann; Christoph Huber; Karin Kolbe; Wolfgang Herr
Reduced-intensity conditioning followed by allografting of CD34-selected stem cells and < or =10(6)/kg T cells may have an adverse effect on transplant-related mortality.
Annals of hematology 2005;84(5):331-8.
2005: Ralf G Meyer; Cedrik Michael Britten; Ulrike Siepmann; Barbara Petzold; Tolga A Sagban; Hans-Anton Lehr; Bernd Weigle; Marc Schmitz; Luis Mateo; Burkhard Schmidt; Helga Bernhard; Thilo Jakob; Rüdiger Hein; Gerold Schuler; Beatrice Schuler-Thurner; Stephan N Wagner; Ingo Drexler; Gerd Sutter; Nathaly Arndtz; Paul Chaplin; Jost Metz; Alexander Enk; Christoph Huber; Thomas Wölfel
A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr).
Cancer immunology, immunotherapy : CII 2005;54(5):453-67.
2005: Cedrik Michael Britten; Ralf G Meyer; Claudine Graf; Christoph Huber; Thomas Wölfel
Identification of T cell epitopes by the use of rapidly generated mRNA fragments.
Journal of immunological methods 2005;299(1-2):165-75.
2005: Christoph Huber; N Bobek; Jürgen Kuball; S Thaler; Sandra Hoffarth; C Huber; Matthias Theobald; Martin Schuler
Inhibitors of apoptosis confer resistance to tumour suppression by adoptively transplanted cytotoxic T-lymphocytes in vitro and in vivo.
Cell death and differentiation 2005;12(4):317-25.
2005: Johanna E A Portielje; Wim H J Kruit; Anke J M Eerenberg; Martin Schuler; Alex Sparreboom; Cor H J Lamers; Jan W Gratama; Gerrit Stoter; Christoph Huber; C Erik Hack
Subcutaneous injection of interleukin 12 induces systemic inflammatory responses in humans: implications for the use of IL-12 as vaccine adjuvant.
Cancer immunology, immunotherapy : CII 2005;54(1):37-43.
2005: Jürgen Kuball; Frank W Schmitz; Ralf-Holger Voss; Edite Antunes Ferreira; Renate Engel; Philippe Guillaume; Susanne Strand; Pedro Romero; Christoph Huber; Linda A Sherman; Matthias Theobald
Cooperation of human tumor-reactive CD4+ and CD8+ T cells after redirection of their specificity by a high-affinity p53A2.1-specific TCR.
Immunity 2005;22(1):117-29.
2005: Thomas Kindler; Frank Breitenbuecher; Stefan Kasper; Elihu Estey; Francis Giles; Eric Feldman; Gerhard Ehninger; Gary Schiller; Virginia Klimek; Stephen D Nimer; Alois Gratwohl; Chunaram Choudhary; Constan Mueller-Tidow; Hubert Serve; Harald Gschaidmeier; Pamela S Cohen; Christoph Huber; Thomas Fischer
Identification of a novel activating mutation (Y842C) within the activation loop of FLT3 in patients with acute myeloid leukemia (AML).
Blood 2005;105(1):335-40.
2004: Andreas Dörrschuck; Andrea Schmidt; Elke Schnürer; Matthias Glückmann; Christian Albrecht; Catherine Wölfel; Volker Lennerz; Alexander Lifke; Carmela Di Natale; Elena Ranieri; Loreto Gesualdo; Christoph Huber; Michael Karas; Thomas Wölfel; Wolfgang Herr
CD8+ cytotoxic T lymphocytes isolated from allogeneic healthy donors recognize HLA class Ia/Ib-associated renal carcinoma antigens with ubiquitous or restricted tissue expression.
Blood 2004;104(8):2591-9.
2004: Michael Koslowski; Carolin Bell; Gerhard Seitz; Hans-Anton Lehr; Klaus Roemer; Horst Müntefering; Christoph Huber; Ugur Sahin; Ozlem Türeci
Frequent nonrandom activation of germ-line genes in human cancer.
Cancer research 2004;64(17):5988-93.
2004: Ozlem Türeci; Uli Luxemburger; Helma Heinen; Ulrich Mack; Gerhard W Sybrecht; Christoph Huber; Ugur Sahin
CrELISA: a fast and robust enzyme-linked immunosorbent assay bypassing the need for purification of recombinant protein.
Journal of immunological methods 2004;289(1-2):191-9.
2004: Thomas Kindler; Frank Breitenbuecher; Andreas Marx; Joachim Beck; Georg Hess; Birgit Weinkauf; Justus Duyster; Christian Peschel; Charles James Kirkpatrick; Matthias Theobald; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia.
Blood 2004;103(10):3644-54.
2004: Cedrik Michael Britten; Ralf G Meyer; Nadine Frankenberg; Christoph Huber; Thomas Wölfel
The use of clonal mRNA as an antigenic format for the detection of antigen-specific T lymphocytes in IFN-gamma ELISPOT assays.
Journal of immunological methods 2004;287(1-2):125-36.
2004: Carina Lotz; Edite Antunes Ferreira; Ingo Drexler; Sarah Abdel Mutallib; Christoph Huber; Gerd Sutter; Matthias Theobald
Partial tyrosinase-specific self tolerance by HLA-A*0201-restricted cytotoxic T lymphocytes in mice and man.
International journal of cancer. Journal international du cancer 2004;108(4):571-9.
2003: Patricia Krause; Ozlem Türeci; Patrick Micke; Roland Buhl; Christoph Huber; Ugur Sahin
SeroGRID: an improved method for the rapid selection of antigens with disease related immunogenicity.
Journal of immunological methods 2003;283(1-2):261-7.
2003: Jürgen Bukur; Barbara Malenica; Christoph Huber; Barbara Seliger
Altered expression of nonclassical HLA class Ib antigens in human renal cell carcinoma and its association with impaired immune response.
Human immunology 2003;64(11):1081-92.
2003: Isabelle Hodson; Michaela Bock; Ulrike Ritz; Walburgis Brenner; Christoph Huber; Barbara Seliger
Analysis of the structural integrity of the TAP2 gene in renal cell carcinoma.
International journal of oncology 2003;23(4):991-9.
2003: Andrew J Ullmann; Georg Hess; Karin Kolbe; A Friedrich-Freksa; Ralf G Meyer; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
Current results on the use of imatinib mesylate in patients with relapsed Philadelphia chromosome positive leukemia after allogeneic or syngeneic hematopoietic stem cell transplantation.
The Keio journal of medicine 2003;52(3):182-8.
2003: Felix Herrmann; John Trowsdale; Christoph Huber; Barbara Seliger
Cloning and functional analyses of the mouse tapasin promoter.
Immunogenetics 2003;55(6):379-88.
2003: Jürgen Bukur; Vera Rebmann; Hans Grosse-Wilde; Hans Luboldt; Herbert Ruebben; Ingo Drexler; Gerd Sutter; Christoph Huber; Barbara Seliger
Functional role of human leukocyte antigen-G up-regulation in renal cell carcinoma.
Cancer research 2003;63(14):4107-11.
2003: Thomas Kindler; Frank Breitenbuecher; Stefan Kasper; T Stevens; B Carius; Harald Gschaidmeier; Christoph Huber; Thomas Fischer
In BCR-ABL-positive cells, STAT-5 tyrosine-phosphorylation integrates signals induced by imatinib mesylate and Ara-C.
Leukemia 2003;17(6):999-1009.
2003: Barbara Seliger; Derek Atkins; Michaela Bock; Ulrike Ritz; Soldano Ferrone; Christoph Huber; Stephan Störkel
Characterization of human lymphocyte antigen class I antigen-processing machinery defects in renal cell carcinoma lesions with special emphasis on transporter-associated with antigen-processing down-regulation.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(5):1721-7.
2003: Georg Hess; Thomas Flohr; Christoph Huber; Karin Kolbe; Hans Günter Derigs; Thomas Fischer
Safety and feasibility of CHOP/rituximab induction treatment followed by high-dose chemo/radiotherapy and autologous PBSC-transplantation in patients with previously untreated mantle cell or indolent B-cell-non-Hodgkin's lymphoma.
Bone marrow transplantation 2003;31(9):775-82.
2003: Thomas Kindler; Frank Breitenbuecher; Andreas Marx; Georg Hess; Harald Gschaidmeier; Heinold Gamm; Charles James Kirkpatrick; Christoph Huber; Thomas Fischer
Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML.
Blood 2003;101(8):2960-2.
2003: Ulrike Ritz; Ingo Drexler; Dirk Sutter; Rupert Abele; Christoph Huber; Barbara Seliger
Impaired transporter associated with antigen processing (TAP) function attributable to a single amino acid alteration in the peptide TAP subunit TAP1.
Journal of immunology (Baltimore, Md. : 1950) 2003;170(2):941-6.
2003: Johanna E A Portielje; Cor H J Lamers; Wim H J Kruit; Alex Sparreboom; Reinder L H Bolhuis; Gerrit Stoter; Christoph Huber; Jan W Gratama
Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(1):76-83.
2002: Michael Koslowski; Ozlem Türeci; Carolin Bell; Patricia Krause; Hans-Anton Lehr; Joachim Brunner; Gerhard Seitz; Frank O Nestle; Christoph Huber; Ugur Sahin
Multiple splice variants of lactate dehydrogenase C selectively expressed in human cancer.
Cancer research 2002;62(22):6750-5.
2002: Wolf-Karsten Hofmann; Gernot Seipelt; S Langenhan; Regina Reutzel; D Schott; O Schoeffski; Hans-Jochen Illiger; Frank Hartmann; Leopold Balleisen; Astrid Franke; Friedrich Fiedler; Christoph Huber; Herbert Rasche; Lothar Bergmann; Arnold Ganser; Christiane Pott; Rita Pasold; C Rudolph; Oliver G Ottmann; Nicola Gökbuget; Dieter Hoelzer
Prospective randomized trial to evaluate two delayed granulocyte colony stimulating factor administration schedules after high-dose cytarabine therapy in adult patients with acute lymphoblastic leukemia.
Annals of hematology 2002;81(10):570-4.
2002: Thomas Fischer; C Reifenrath; G R Hess; Maria T Corsetti; Sebastian Kreil; J Beck; P Meinhardt; Germana Beltrami; B Schuch; Harald Gschaidmeier; Rüdiger Hehlmann; Andreas Hochhaus; A Carella; Christoph Huber
Safety and efficacy of STI-571 (imatinib mesylate) in patients with bcr/abl-positive chronic myelogenous leukemia (CML) after autologous peripheral blood stem cell transplantation (PBSCT).
Leukemia 2002;16(7):1220-8.
2002: Jürgen Kuball; Martin Schuler; E Antunes Ferreira; Wolfgang Herr; M Neumann; L Obenauer-Kutner; L Westreich; Christoph Huber; Thomas Wölfel; Matthias Theobald
Generating p53-specific cytotoxic T lymphocytes by recombinant adenoviral vector-based vaccination in mice, but not man.
Gene therapy 2002;9(13):833-43.
2002: Thomas Flohr; Georg Hess; Karin Kolbe; Heinold Gamm; H Nolte; T Stanislawski; Christoph Huber; Hans Günter Derigs
Rituximab in vivo purging is safe and effective in combination with CD34-positive selected autologous stem cell transplantation for salvage therapy in B-NHL.
Bone marrow transplantation 2002;29(9):769-75.
2002: Jürgen Kuball; Shu Fen Wen; Joachim Leissner; Derek Atkins; Patricia Meinhardt; Erlinda Quijano; Heidrun Engler; Beth Hutchins; Daniel Maneval; Michael J Grace; Mary Ann Fritz; Stephan Störkel; Joachim W Thüroff; Christoph Huber; Martin Schuler
Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(4):957-65.
2002: Barbara Seliger; Michaela Bock; Ulrike Ritz; Christoph Huber
High frequency of a non-functional TAP1/LMP2 promoter polymorphism in human tumors.
International journal of oncology 2002;20(2):349-53.
2001: Barbara Seliger; Ulrike Ritz; Rupert Abele; Michaela Bock; Robert Tampé; Gerd Sutter; Ingo Drexler; Christoph Huber; Soldano Ferrone
Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway.
Cancer research 2001;61(24):8647-50.
2001: Jun Li; B Schuler-Thurner; G Schuler; Christoph Huber; Barbara Seliger
Bipartite regulation of different components of the MHC class I antigen-processing machinery during dendritic cell maturation.
International immunology 2001;13(12):1515-23.
2001: Ulrike Ritz; F Momburg; Henryk Pilch; Christoph Huber; Markus J Maeurer; Barbara Seliger
Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma.
International journal of oncology 2001;19(6):1211-20.
2001: Udo Hartwig; U Keller; Christoph Huber; Christian Peschel
Regulation of hematopoietic growth factor production by genetically modified human bone marrow stromal cells expressing interleukin-1beta antisense RNA.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 2001;21(10):851-60.
2001: Jürgen Kuball; Christoph Huber; Martin Schuler
[Gene therapy of solid tumors].
Der Internist 2001;42(10):1321-7.
2001: T Stanislawski; Ralf-Holger Voss; Carina Lotz; Elena Sadovnikova; Ralph A Willemsen; Jürgen Kuball; Thomas Ruppert; Reinder L H Bolhuis; Cornelis J M Melief; Christoph Huber; Hans J Stauss; Matthias Theobald
Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer.
Nature immunology 2001;2(10):962-70.
2001: Sebastian Kreiter; N Winkelmann; Peter M Schneider; Martin Schuler; Thomas Fischer; Andrew J Ullmann; Christoph Huber; Hans Günter Derigs; Karin Kolbe
Failure of sustained engraftment after non-myeloablative conditioning with low-dose TBI and T cell-reduced allogeneic peripheral stem cell transplantation.
Bone marrow transplantation 2001;28(2):157-61.
2001: Martin Schuler; Richard Herrmann; J L De Greve; A K Stewart; U Gatzemeier; D J Stewart; L Laufman; Richard J Gralla; Jürgen Kuball; R Buhl; Claus Peter Heussel; Friedrich Kommoss; A P Perruchoud; F A Shepherd; Mary Ann Fritz; J A Horowitz; Christoph Huber; C Rochlitz
Adenovirus-mediated wild-type p53 gene transfer in patients receiving chemotherapy for advanced non-small-cell lung cancer: results of a multicenter phase II study.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(6):1750-8.
2001: Barbara Seliger; Ursula Wollscheid; F Momburg; Thomas Blankenstein; Christoph Huber
Characterization of the major histocompatibility complex class I deficiencies in B16 melanoma cells.
Cancer research 2001;61(3):1095-9.
2001: Johanna E A Portielje; Wim H J Kruit; Anke J M Eerenberg; M Schuler; Alex Sparreboom; C H Lamers; Reinder L H Bolhuis; Gerrit Stoter; Christoph Huber; C Erik Hack
Interleukin 12 induces activation of fibrinolysis and coagulation in humans.
British journal of haematology 2001;112(2):499-505.
2001: Barbara Seliger; K Schreiber; K Delp; M Meissner; S Hammers; T Reichert; K Pawlischko; Robert Tampé; Christoph Huber
Downregulation of the constitutive tapasin expression in human tumor cells of distinct origin and its transcriptional upregulation by cytokines.
Tissue antigens 2001;57(1):39-45.
2001: Ulrike Ritz; F Momburg; H P Pircher; Dennis Strand; Christoph Huber; Barbara Seliger
Identification of sequences in the human peptide transporter subunit TAP1 required for transporter associated with antigen processing (TAP) function.
International immunology 2001;13(1):31-41.
2000: Charles Craddock; P Bardy; Sebastian Kreiter; R Johnston; Jane Apperley; D Marks; Christoph Huber; Karin Kolbe; R Goulding; M Lawler; J Goldman; T Hughes; G Derigs
Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen.
British journal of haematology 2000;111(3):797-800.
2000: Sebastian Kreiter; Thomas Wehler; O Landt; Christoph Huber; Hans Günter Derigs; Georg Hess
Rapid identification of minor histocompatibility antigen HA-1 subtypes H and R using fluorescence-labeled oligonucleotides.
Tissue antigens 2000;56(5):449-52.
2000: Catherine Wölfel; Ingo Drexler; Aline Van Pel; T Thres; N Leister; Wolfgang Herr; Gerd Sutter; Christoph Huber; Thomas Wölfel
Transporter (TAP)- and proteasome-independent presentation of a melanoma-associated tyrosinase epitope.
International journal of cancer. Journal international du cancer 2000;88(3):432-8.
2000: Barbara Seliger; Ursula Wollscheid; F Momburg; Thomas Blankenstein; Christoph Huber
Coordinate downregulation of multiple MHC class I antigen processing genes in chemical-induced murine tumor cell lines of distinct origin.
Tissue antigens 2000;56(4):327-36.
2000: D Després; Thomas Flohr; Michael Uppenkamp; M Baldus; M Hoffmann; Christoph Huber; Hans Günter Derigs
CD34+ cell enrichment for autologous peripheral blood stem cell transplantation by use of the CliniMACs device.
Journal of hematotherapy & stem cell research 2000;9(4):557-64.
2000: Barbara Seliger; Y Rongcun; Derek Atkins; S Hammers; Christoph Huber; Stephan Störkel; Rolf Kiessling
HER-2/neu is expressed in human renal cell carcinoma at heterogeneous levels independently of tumor grading and staging and can be recognized by HLA-A2.1-restricted cytotoxic T lymphocytes.
International journal of cancer. Journal international du cancer 2000;87(3):349-59.
2000: K Delp; F Momburg; C Hilmes; Christoph Huber; Barbara Seliger
Functional deficiencies of components of the MHC class I antigen pathway in human tumors of epithelial origin.
Bone marrow transplantation 2000;25 Suppl 2():S88-95.
2000: Georg Hess; C Reifenrath; A Friedrich-Freksa; V Beyer; Steffen Naumann; B Schuch; Christoph Huber; T Fischer; Hans-Jochen Decker
Autologous transplantation of in vivo purged PBSC in CML: comparison of FISH, cytogenetics, and PCR detection of Philadelphia chromosome in leukapheresis products.
Cancer genetics and cytogenetics 2000;117(1):1-8.
1999: Johanna E A Portielje; Wim H J Kruit; Martin Schuler; J Beck; Cor H J Lamers; Gerrit Stoter; Christoph Huber; M de Boer-Dennert; A Rakhit; Reinder L H Bolhuis; Walter Aulitzky
Phase I study of subcutaneously administered recombinant human interleukin 12 in patients with advanced renal cell cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3983-9.
1999: M Lindauer; D Domkin; H Döhner; H J Kolb; A Neubauer; Dieter Huhn; H Kreiter; B Koch; Christoph Huber; Walter Aulitzky; T Fischer
Efficacy and toxicity of IFN-alpha2b combined with cytarabine in chronic myelogenous leukaemia.
British journal of haematology 1999;106(4):1013-9.
1999: G Göllner; G Bug; B Rupilius; Christian Peschel; Christoph Huber; Hans Günter Derigs
Regulatory elements of the leukaemia inhibitory factor (LIF) promoter in murine bone marrow stromal cells.
Cytokine 1999;11(9):656-63.
1999: D Jung; C Hilmes; Alexander Knuth; E Jaeger; Christoph Huber; Barbara Seliger
Gene transfer of the Co-stimulatory molecules B7-1 and B7-2 enhances the immunogenicity of human renal cell carcinoma to a different extent.
Scandinavian journal of immunology 1999;50(3):242-9.
1999: Jürgen Brieger; EJ Weidt; Peter Schirmacher; Stephan Störkel; Christoph Huber; Hans-Jochen Decker
Inverse regulation of vascular endothelial growth factor and VHL tumor suppressor gene in sporadic renal cell carcinomas is correlated with vascular growth: an in vivo study on 29 tumors.
Journal of molecular medicine (Berlin, Germany) 1999;77(6):505-10.
1999: R F Schwerdtle; C Neuhaus; EJ Weidt; Christoph Huber; W Brenner; Rudolf Hohenfellner; Andreas Winterpacht; B Zabel; Hans-Jochen Decker; Stephan Störkel; Hiltrud Brauch
Retraction.
Cancer research 1999;59(8):2021.
1999: H van der Kuip; B Carius; S J Haque; B R Williams; Christoph Huber; T Fischer
The DNA-binding subunit p140 of replication factor C is upregulated in cycling cells and associates with G1 phase cell cycle regulatory proteins.
Journal of molecular medicine (Berlin, Germany) 1999;77(4):386-92.
1999: U Brass; T Tretter; Folker Schneller; Martin Schuler; Christoph Huber; Christian Peschel
IFN-alpha stimulates proliferation and cytokine secretion of CD40-stimulated B cell chronic lymphocytic leukemia cells in vitro.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1999;19(4):335-43.
1999: M Kallfelz; D Jung; C Hilmes; Alexander Knuth; E Jaeger; Christoph Huber; Barbara Seliger
Induction of immunogenicity of a human renal-cell carcinoma cell line by TAP1-gene transfer.
International journal of cancer. Journal international du cancer 1999;81(1):125-33.
1999: Martin Schuler; T Tretter; Folker Schneller; Christoph Huber; Christian Peschel
Autocrine transforming growth factor-beta from chronic lymphocytic leukemia-B cells interferes with proliferative T cell signals.
Immunobiology 1999;200(1):128-39.
1998: Folker Schneller; Martin Schuler; K Schumacher; J Thaler; Christian Peschel; Christoph Huber; Walter Aulitzky
Idarubicin and intermediate-dose cytarabine for myeloid blast crisis of chronic myelogenous leukemia--results of a phase-II trial.
Annals of hematology 1998;77(5):225-9.
1998: T Tretter; Martin Schuler; Folker Schneller; U Brass; M Esswein; MJ Aman; Christoph Huber; Christian Peschel
Direct cellular interaction with activated CD4(+) T cells overcomes hyporesponsiveness of B-cell chronic lymphocytic leukemia in vitro.
Cellular immunology 1998;189(1):41-50.
1998: Matthias Theobald; Thomas Ruppert; Ulrike Kuckelkorn; J Hernandez; A Häussler; Edite Antunes Ferreira; Ulrike Liewer; Judith A Biggs; Arnold J Levine; Christoph Huber; Ulrich H Koszinowski; Peter-M Kloetzel; Linda A Sherman
The sequence alteration associated with a mutational hotspot in p53 protects cells from lysis by cytotoxic T lymphocytes specific for a flanking peptide epitope.
The Journal of experimental medicine 1998;188(6):1017-28.
1998: Martin Schuler; C Rochlitz; J A Horowitz; J Schlegel; A P Perruchoud; Friedrich Kommoss; C T Bolliger; H U Kauczor; P Dalquen; Mary Ann Fritz; S Swanson; Richard Herrmann; Christoph Huber
A phase I study of adenovirus-mediated wild-type p53 gene transfer in patients with advanced non-small cell lung cancer.
Human gene therapy 1998;9(14):2075-82.
1998: E Neumann; A Engelsberg; J Decker; Stephan Störkel; E Jaeger; Christoph Huber; Barbara Seliger
Heterogeneous expression of the tumor-associated antigens RAGE-1, PRAME, and glycoprotein 75 in human renal cell carcinoma: candidates for T-cell-based immunotherapies?
Cancer research 1998;58(18):4090-5.
1998: Thomas Fischer; A Neubauer; J Mohm; Dieter Huhn; C Busemann; H Link; Lubomir Arseniev; B Büssing; J Novotny; Arnold Ganser; Justus Duyster; D Bunjes; T Westermeier; Thomas Flohr; D Desprès; Heinold Gamm; J Decker; G Derigs; Walter Aulitzky; Christoph Huber
Outcome of peripheral blood stem cell mobilization in advanced phases of CML is dependent on the type of chemotherapy applied.
Annals of hematology 1998;77(1-2):21-6.
1998: Thomas Fischer; A Neubauer; J Mohm; Dieter Huhn; C Busemann; H Link; Lubomir Arseniev; B Büssing; J Novotny; Arnold Ganser; Justus Duyster; D Bunjes; Sebastian Kreiter; Walter Aulitzky; Rüdiger Hehlmann; Christoph Huber
Chemotherapy-induced mobilization of karyotypically normal PBSC for autografting in CML.
Bone marrow transplantation 1998;21(10):1029-36.
1998: T Tretter; MJ Aman; G Bug; Christoph Huber; Christian Peschel
Hematopoietic growth factors are differentially regulated in monocytes and CD4+ T lymphocytes: influence of IFN-alpha and interleukin-4.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1998;18(2):95-102.
1998: G Bug; MJ Aman; T Tretter; Christoph Huber; Christian Peschel
Induction of macrophage-inflammatory protein 1alpha (MIP-1alpha) by interferon-alpha.
Experimental hematology 1998;26(2):117-23.
1998: M Heuser; H van der Kuip; B Falini; Christian Peschel; Christoph Huber; T Fischer
Induction of the pro-myelocytic leukaemia gene by type I and type II interferons.
Mediators of inflammation 1998;7(5):319-25.
1998: G Bug; J Aman; Christoph Huber; Christian Peschel; Hans Günter Derigs
cAMP analogues downregulate the expression of granulocyte macrophage colony-stimulating factor (GM-CSF) in human bone marrow stromal cells in vitro.
Mediators of inflammation 1998;7(3):195-9.
1998: Barbara Seliger; C Harders; S Lohmann; F Momburg; S Urlinger; Robert Tampé; Christoph Huber
Down-regulation of the MHC class I antigen-processing machinery after oncogenic transformation of murine fibroblasts.
European journal of immunology 1998;28(1):122-33.
1998: M Lindauer; T Stanislawski; A Häussler; E Antunes; A Cellary; Christoph Huber; Matthias Theobald
The molecular basis of cancer immunotherapy by cytotoxic T lymphocytes.
Journal of molecular medicine (Berlin, Germany) 1998;76(1):32-47.
1998: D Jung; E Jaeger; S Cayeux; Thomas Blankenstein; C Hilmes; Julia Karbach; U Moebius; Alexander Knuth; Christoph Huber; Barbara Seliger
Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes.
Human gene therapy 1998;9(1):53-62.
1997: Karin Kolbe; Christian Peschel; B Rupilius; D Després; KJ Burger; I Sklenar; Lothar Färber; Christoph Huber; Hans Günter Derigs
Peripheral blood stem cell (PBSC) mobilization with chemotherapy followed by sequential IL-3 and G-CSF administration in extensively pretreated patients.
Bone marrow transplantation 1997;20(12):1027-32.
1997: Barbara Seliger; T Dunn; A Schwenzer; J Casper; Christoph Huber; H J Schmoll
Analysis of the MHC class I antigen presentation machinery in human embryonal carcinomas: evidence for deficiencies in TAP, LMP and MHC class I expression and their upregulation by IFN-gamma.
Scandinavian journal of immunology 1997;46(6):625-32.
1997: R F Schwerdtle; Andreas Winterpacht; Stephan Störkel; Walburgis Brenner; Rudolf Hohenfellner; Bernhard Zabel; Christoph Huber; Hans-Jochen Decker
Loss of heterozygosity studies and deletion mapping identify two putative chromosome 14q tumor suppressor loci in renal oncocytomas.
Cancer research 1997;57(22):5009-12.
1997: Barbara Seliger; A Höhne; D Jung; M Kallfelz; Alexander Knuth; E Jaeger; H Bernhard; F Momburg; Robert Tampé; Christoph Huber
Expression and function of the peptide transporters in escape variants of human renal cell carcinomas.
Experimental hematology 1997;25(7):608-14.
1997: Barbara Seliger; S Hammers; A Höhne; R Zeidler; Alexander Knuth; C D Gerharz; Christoph Huber
IFN-gamma-mediated coordinated transcriptional regulation of the human TAP-1 and LMP-2 genes in human renal cell carcinoma.
Clinical cancer research : an official journal of the American Association for Cancer Research 1997;3(4):573-8.
1997: C Neuhaus; Trijnie Dijkhuizen; Eva van den Berg; Stephan Störkel; M Stöckle; B Mensch; Christoph Huber; Hans-Jochen Decker
Involvement of the chromosomal region 11q13 in renal oncocytoma: case report and literature review.
Cancer genetics and cytogenetics 1997;94(2):95-8.
1997: Karin Kolbe; D Domkin; Hans Günter Derigs; S Bhakdi; Christoph Huber; Walter Aulitzky
Infectious complications during neutropenia subsequent to peripheral blood stem cell transplantation.
Bone marrow transplantation 1997;19(2):143-7.
1996: T Albrecht; R Schwab; M Henkes; Christian Peschel; Christoph Huber; Walter Aulitzky
Primary proliferating immature myeloid cells from CML patients are not resistant to induction of apoptosis by DNA damage and growth factor withdrawal.
British journal of haematology 1996;95(3):501-7.
1996: M J Aman; K Stockdreher; A Thews; K Kienast; Walter Aulitzky; Lothar Färber; Ulrike Haus; B Koci; Christoph Huber; Christian Peschel
Regulation of immunomodulatory functions by granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor in vivo.
Annals of hematology 1996;73(5):231-8.
1996: Martin Schuler; Christian Peschel; Folker Schneller; Jan Fichtner; Lothar Färber; Christoph Huber; Walter Aulitzky
Immunomodulatory and hematopoietic effects of recombinant human interleukin-6 in patients with advanced renal cell cancer.
Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research 1996;16(11):903-10.
1996: Michael Heike; U Schmitt; A Höhne; Christoph Huber; K H Meyer zum Büschenfelde
Impaired HLA-class-I stability in a sarcoma cell line which stimulates exclusively HLA-class-II-restricted autologous T cells.
International journal of cancer. Journal international du cancer 1996;67(5):743-8.
1996: Barbara Seliger; S Papadileris; D Vogel; G Hess; C Brendel; S Störkel; J Ortel; Karin Kolbe; Christoph Huber; Dieter Huhn; Andreas Neubauer
Analysis of the p53 and MDM-2 gene in acute myeloid leukemia.
European journal of haematology 1996;57(3):230-40.
1996: Barbara Seliger; C Harders; U Wollscheid; Martin Staege; Angelika B Reske-Kunz; Christoph Huber
Suppression of MHC class I antigens in oncogenic transformants: association with decreased recognition by cytotoxic T lymphocytes.
Experimental hematology 1996;24(11):1275-9.
1996: H Bernhard; Markus J Maeurer; Elke Jäger; Thomas Wölfel; J Schneider; Julia Karbach; Barbara Seliger; Christoph Huber; W S Storkus; Michael T Lotze; K H Meyer zum Büschenfelde; Alexander Knuth
Recognition of human renal cell carcinoma and melanoma by HLA-A2-restricted cytotoxic T lymphocytes is mediated by shared peptide epitopes and up-regulated by interferon-gamma.
Scandinavian journal of immunology 1996;44(3):285-92.
1996: Barbara Seliger; A Höhne; Alexander Knuth; H Bernhard; B Ehring; Robert Tampé; Christoph Huber
Reduced membrane major histocompatibility complex class I density and stability in a subset of human renal cell carcinomas with low TAP and LMP expression.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(8):1427-33.
1996: J Lorenz; K Wilhelm; M Kessler; C Peschel; U Schwulera; R Lissner; Wilhelm G. Struff; Edith Huland; Christoph Huber; Walter Aulitzky
Phase I trial of inhaled natural interleukin 2 for treatment of pulmonary malignancy: toxicity, pharmacokinetics, and biological effects.
Clinical cancer research : an official journal of the American Association for Cancer Research 1996;2(7):1115-22.
1996: M J Aman; G Bug; Walter Aulitzky; Christoph Huber; Christian Peschel
Inhibition of interleukin-11 by interferon-alpha in human bone marrow stromal cells.
Experimental hematology 1996;24(8):863-7.
1996: R F Schwerdtle; Stephan Störkel; C Neuhaus; H Brauch; EJ Weidt; W Brenner; Rudolf Hohenfellner; Christoph Huber; Hans-Jochen Decker
Allelic losses at chromosomes 1p, 2p, 6p, 10p, 13q, 17p, and 21q significantly correlate with the chromophobe subtype of renal cell carcinoma.
Cancer research 1996;56(13):2927-30.
1996: Josef Thaler; Guenther Gastl; T Fluckinger; Dietger Niederwieser; Heinz Huber; HL Seewann; Heinz Sill; A Lang; M Falk; C Duba; Gerd Utermann; Thomas Kühr; Walter Aulitzky; Christoph Huber
Interferon alpha-2c therapy of patients with chronic myelogenous leukemia: long-term results of a multicenter phase-II study. Austrian Biological Response Modifier (BRM) Study Group.
Annals of hematology 1996;72(6):349-55.
1996: Hans-Jochen Decker; C Neuhaus; A Jauch; Michael R Speicher; T Ried; M Bujard; H Brauch; Stephan Störkel; M Stöckle; Barbara Seliger; Christoph Huber
Detection of a germline mutation and somatic homozygous loss of the von Hippel-Lindau tumor-suppressor gene in a family with a de novo mutation. A combined genetic study, including cytogenetics, PCR/SSCP, FISH, and CGH.
Human genetics 1996;97(6):770-6.
1996: M J Aman; T Tretter; I Eisenbeis; G Bug; T Decker; Walter Aulitzky; Herbert Tilg; Christoph Huber; Christian Peschel
Interferon-alpha stimulates production of interleukin-10 in activated CD4+ T cells and monocytes.
Blood 1996;87(11):4731-6.
1996: Walter Aulitzky; Andreas Neubauer; Karin Kolbe; Folker Schneller; C Busemann; E Schleiermacher; Christian Peschel; W Siegert; Christoph Huber; Dieter Huhn
Preliminary results of stem cell mobilization in chronic myeloid leukemia with a moderate intensity chemotherapy regimen and G-CSF or G-CSF plus IL-3.
Bone marrow transplantation 1996;17 Suppl 3():S67-9.
1996: S Lohmann; U Wollscheid; Christoph Huber; Barbara Seliger
Multiple levels of MHC class I down-regulation by ras oncogenes.
Scandinavian journal of immunology 1996;43(5):537-44.
1996: Barbara Seliger; A Hohne; Alexander Knuth; H Bernhard; T Meyer; R Tampe; F Momburg; Christoph Huber
Analysis of the major histocompatibility complex class I antigen presentation machinery in normal and malignant renal cells: evidence for deficiencies associated with transformation and progression.
Cancer research 1996;56(8):1756-60.
1996: Hans Günter Derigs; Christoph Huber; M Mahlke; Karin Kolbe
[High dose chemotherapy in treatment of breast carcinoma: current status and limits of this method of therapy].
Geburtshilfe und Frauenheilkunde 1996;56(4):190-7.
1996: Klaus Geissler; Christian Peschel; Dietger Niederwieser; Herbert Strobl; J Goldschmitt; Leopold Ohler; P Bettelheim; P Kahls; Christoph Huber; Klaus Lechner; Paul Höcker; Karin Kolbe
Potentiation of granulocyte colony-stimulating factor-induced mobilization of circulating progenitor cells by seven-day pretreatment with interleukin-3.
Blood 1996;87(7):2732-9.
1996: S Jaharul Haque; H van der Kuip; A Kumar; Walter Aulitzky; M N Rutherford; Christoph Huber; Thomas Fischer; Bryan R G Williams
Overexpression of mouse p140 subunit of replication factor C accelerates cellular proliferation.
Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996;7(3):319-26.
1996: Thomas Fischer; J Aman; H van der Kuip; G Rudolf; Christian Peschel; Walter Aulitzky; Christoph Huber
Induction of interferon regulatory factors 2'-5' oligoadenylate synthetase, P68 kinase and RNase L in chronic myelogenous leukaemia cells and its relationship to clinical responsiveness.
British journal of haematology 1996;92(3):595-603.
1996: Oliver Thews; A Thews; Christoph Huber; P Vaupel
Computer-assisted interpretation of flow cytometry data in hematology.
Cytometry 1996;23(2):140-9.
1996: T Albrecht; R Schwab; Christian Peschel; H J Engels; Thomas Fischer; Christoph Huber; Walter Aulitzky
Cationic lipid mediated transfer of c-abl and bcr antisense oligonucleotides to immature normal myeloid cells: uptake, biological effects and modulation of gene expression.
Annals of hematology 1996;72(2):73-9.
1996: David Nachbaur; Dietger Niederwieser; G Aichinger; Walter Aulitzky; Herbert Tilg; Brigitte Eibl; P König; C Gattringer; O Majdic; Hannes Stockinger; Raimund Margreiter; G Oberhuber; A M Födinger; Hubert Schwaighofer; Christoph Huber
CD4 monoclonal antibody VIT4 in human alloimmune response in vitro and in vivo.
Immunobiology 1996;195(1):33-46.
1995: R Schwab; Christian Peschel; D Desprès; G Derigs; Thomas Fischer; Christoph Huber; Walter Aulitzky
Deficient cell cycle control in myeloid cells of patients with newly diagnosed chronic myeloid leukemia.
Cytokines and molecular therapy 1995;1(4):281-8.
1995: Martin Schuler; Walter Aulitzky; Folker Schneller; Christian Peschel; Christoph Huber
[Interferon-alpha in therapy of malignant hemoblastoses].
Der Internist 1995;36(12):1133-8.
1995: D Després; J Goldschmitt; Walter Aulitzky; Christoph Huber; Christian Peschel
Differential effect of type I interferons on hematopoietic progenitor cells: failure of interferons to inhibit IL-3-stimulated normal and CML myeloid progenitors.
Experimental hematology 1995;23(14):1431-8.
1995: Klaus Geissler; Christian Peschel; Dietger Niederwieser; J Goldschmitt; F Hladik; A Fritz; Leopold Ohler; P Bettelheim; Christoph Huber; Klaus Lechner
Effect of interleukin-3 pretreatment on granulocyte/macrophage colony-stimulating factor induced mobilization of circulating haemopoietic progenitor cells.
British journal of haematology 1995;91(2):299-305.
1995: H Schönbohn; Martin Schuler; Karin Kolbe; Christian Peschel; Christoph Huber; W Bemb; Walter Aulitzky
Plasma levels of IL-1, TNF alpha, IL-6, IL-8, G-CSF, and IL1-RA during febrile neutropenia: results of a prospective study in patients undergoing chemotherapy for acute myelogenous leukemia.
Annals of hematology 1995;71(4):161-8.
1995: G Göllner; M J Aman; Hans-Peter Steffens; Christoph Huber; Christian Peschel; Hans Günter Derigs
Interferon-alpha (IFN-alpha) inhibits granulocyte-macrophage colony-stimulating factor (GM-CSF) expression at the post-transcriptional level in murine bone marrow stromal cells.
British journal of haematology 1995;91(1):8-14.
1995: Martin Schuler; Christoph Huber; Christian Peschel
Cytokines in the pathophysiology and treatment of chronic B-cell malignancies. A review.
Annals of hematology 1995;71(2):57-63.
1995: T Decker; Thomas Flohr; P Trautmann; M J Aman; W Holter; O Majdic; Christoph Huber; Christian Peschel
Role of accessory cells in cytokine production by T cells in chronic B-cell lymphocytic leukemia.
Blood 1995;86(3):1115-23.
1995: Brigitte Eibl; E Greiter; Kurt Grünewald; Guenther Gastl; K Weyrer; Josef Thaler; Walter Aulitzky; F Herrmann; U Rapp; Christoph Huber
Expression of c-fos correlates with IFN-alpha responsiveness in Philadelphia chromosome positive chronic myelogenous leukemia.
Cytokines and molecular therapy 1995;1(1):29-38.
1995: Walter Aulitzky; Christian Peschel; Folker Schneller; Christoph Huber
Biotherapy of chronic myelogenous leukemia.
Annals of hematology 1995;70(3):113-20.
1994: M Schuler; Jan G Hengstler; F Oesch; Christoph Huber
[Secondary neoplasia after immunosuppression].
Deutsche medizinische Wochenschrift (1946) 1994;119(50):1747-54.
1994: M J Aman; U Keller; G Derigs; M Mohamadzadeh; Christoph Huber; Christian Peschel
Regulation of cytokine expression by interferon-alpha in human bone marrow stromal cells: inhibition of hematopoietic growth factors and induction of interleukin-1 receptor antagonist.
Blood 1994;84(12):4142-50.
1994: H Bernhard; Julia Karbach; Thomas Wölfel; P Busch; S Störkel; M Stöckle; C Wölfel; Barbara Seliger; Christoph Huber; K H Meyer zum Büschenfelde
Cellular immune response to human renal-cell carcinomas: definition of a common antigen recognized by HLA-A2-restricted cytotoxic T-lymphocyte (CTL) clones.
International journal of cancer. Journal international du cancer 1994;59(6):837-42.
1994: G Hess; P Rose; H Gamm; S Papadileris; Christoph Huber; Barbara Seliger
Molecular analysis of the erythropoietin receptor system in patients with polycythaemia vera.
British journal of haematology 1994;88(4):794-802.
1994: Walter Aulitzky; Martin Schuler; Christian Peschel; Christoph Huber
Interleukins. Clinical pharmacology and therapeutic use.
Drugs 1994;48(5):667-77.
1994: C Peschel; M J Aman; Christoph Huber
Interferon-alpha as an antagonist to proinflammatory and hematopoietic cytokines.
Journal of interferon research 1994;14(5):289-90.
1994: U Keller; M J Aman; G Derigs; Christoph Huber; Christian Peschel
Human interleukin-4 enhances stromal cell-dependent hematopoiesis: costimulation with stem cell factor.
Blood 1994;84(7):2189-96.
1994: F Hladik; J A Tratkiewicz; Herbert Tilg; W Vogel; U Schwulera; M Krönke; Walter Aulitzky; Christoph Huber
Biologic activity of low dosage IL-2 treatment in vivo. Molecular assessment of cytokine network interaction.
Journal of immunology (Baltimore, Md. : 1950) 1994;153(4):1449-54.
1994: Christian Peschel; Christoph Huber; Walter Aulitzky
Clinical applications of cytokines.
Presse médicale (Paris, France : 1983) 1994;23(23):1083-91.
1994: M Ritter; Christoph Huber; J Auböck; H Pohl-Markl; J Troppmair; M Herold; Anne Gächter; Walter Nussbaumer; Günther Böck; David Nachbaur
Lytic susceptibility of target cells to cytotoxic T cells is determined by their constitutive major histocompatibility complex class I antigen expression and cytokine-induced activation status.
Immunology 1994;81(4):569-77.
1994: Hans Günter Derigs; Christoph Huber; H J Schmoll
[Stage-oriented therapy in nonseminomatous testicular tumors].
Deutsche medizinische Wochenschrift (1946) 1994;119(5):156-64.
1994: Barbara Seliger; Christoph Huber
[Molecular biology in hematology/oncology].
Der Internist 1994;35(2):130-8.
1993: C Ludescher; Wolfgang Hilbe; Wolfgang Eisterer; E Preuss; Christoph Huber; M Gotwald; Johann Hofmann; Josef Thaler
Activity of P-glycoprotein in B-cell chronic lymphocytic leukemia determined by a flow cytometric assay.
Journal of the National Cancer Institute 1993;85(21):1751-8.
1993: M J Aman; G Rudolf; J Goldschmitt; Walter Aulitzky; C Lam; Christoph Huber; Christian Peschel
Type-I interferons are potent inhibitors of interleukin-8 production in hematopoietic and bone marrow stromal cells.
Blood 1993;82(8):2371-8.
1993: Josef Thaler; T Fluckinger; Heinz Huber; A Lang; C Abbrederis; HL Seewann; H Silly; C Baldinger; C Duba; Christoph Huber
Treatment of 11 patients with chronic myelogenous leukemia with interferon-alpha-2C and low-dose cytosine arabinoside.
Leukemia research 1993;17(8):711-5.
1993: F Hladik; Karin Kolbe; Eveline U Irschick; M J Aman; G Gerken; Lothar Färber; E Liehl; Christian Peschel; Walter Aulitzky; Christoph Huber
IL-2, IL-3, and IFN-gamma differently affect in vivo frequencies of circulating precursors of cytotoxic T lymphocytes (CTL-P).
Annals of hematology 1993;67(2):67-74.
1993: Herbert Tilg; Brigitte Eibl; M Pichl; Anne Gächter; M Herold; J Brankova; Christoph Huber; Dietger Niederwieser
Immune response modulation by pentoxifylline in vitro.
Transplantation 1993;56(1):196-201.
1993: Christian Peschel; M J Aman; G Rudolf; Walter Aulitzky; Christoph Huber
Regulation of the cytokine network by interferon: a potential mechanism of interferon in chronic myelogenous leukemia.
Seminars in hematology 1993;30(3 Suppl 3):28-31.
1993: Walter Aulitzky; D Després; G Rudolf; J Aman; Christian Peschel; Christoph Huber
Recombinant interferon beta in chronic myelogenous leukemia.
Seminars in hematology 1993;30(3 Suppl 3):14-6.
1992: Herbert Tilg; J Nordberg; W Vogel; T A Luger; M Herold; Walter Aulitzky; Raimund Margreiter; Christoph Huber
Circulating serum levels of interleukin 6 and C-reactive protein after liver transplantation.
Transplantation 1992;54(1):142-6.
1992: Herbert Tilg; Alfred Königsrainer; R Krausler; Walter Aulitzky; Raimund Margreiter; G Reibnegger; H Wachter; Christoph Huber
Urinary and pancreatic juice neopterin excretion after combined pancreas-kidney transplantation.
Transplantation 1992;53(4):804-8.
1992: Herbert Tilg; M Ceska; Wolfgang Vogel; M Herold; Raimund Margreiter; Christoph Huber
Interleukin-8 serum concentrations after liver transplantation.
Transplantation 1992;53(4):800-3.
1992: Eveline U Irschick; F Hladik; Dietger Niederwieser; Walter Nussbaumer; E Holler; E Kaminski; Christoph Huber
Studies on the mechanism of tolerance or graft-versus-host disease in allogeneic bone marrow recipients at the level of cytotoxic T-cell precursor frequencies.
Blood 1992;79(6):1622-8.
1991: Walter E Aulitzky; Hans Grosse-Wilde; U Westhoff; Herbert Tilg; W Aulitzky; Guenther Gastl; M Herold; Christoph Huber
Enhanced serum levels of soluble HLA class I molecules are induced by treatment with recombinant interferon-gamma (IFN-gamma).
Clinical and experimental immunology 1991;86(2):236-9.
1991: Mathias M. Mueller; H C Curtius; M Herold; Christoph Huber
Neopterin in clinical practice.
Clinica chimica acta; international journal of clinical chemistry 1991;201(1-2):1-16.
1991: Walter E Aulitzky; Herbert Tilg; W Vogel; W Aulitzky; M Berger; Guenther Gastl; M Herold; Christoph Huber
Acute hematologic effects of interferon alpha, interferon gamma, tumor necrosis factor alpha and interleukin 2.
Annals of hematology 1991;62(1):25-31.
1991: Walter Aulitzky; Herbert Tilg; Guenther Gastl; R Mull; R Flener; W Vogel; M Herold; M Berger; G Judmaier; Christoph Huber
Recombinant tumour necrosis factor alpha administered subcutaneously or intramuscularly for treatment of advanced malignant disease: a phase I trial.
European journal of cancer (Oxford, England : 1990) 1991;27(4):462-7.
1990: Dietger Niederwieser; M Herold; W Woloszczuk; Walter Aulitzky; B Meister; Herbert Tilg; Guenther Gastl; R Bowden; Christoph Huber
Endogenous IFN-gamma during human bone marrow transplantation. Analysis of serum levels of interferon and interferon-dependent secondary messages.
Transplantation 1990;50(4):620-5.
1990: Wolfgang Vogel; Herbert Tilg; M Herold; Otto Dietze; Walter Aulitzky; Raimund Margreiter; Christoph Huber
Cytokine production after liver transplantation.
Transplantation proceedings 1990;22(4):1854.
1990: Dietger Niederwieser; F R Appelbaum; G Gastl; E Gersdorf; B Meister; D Geissler; J A Tratkiewicz; Josef Thaler; Christoph Huber
Inadvertent transmission of a donor's acute myeloid leukemia in bone marrow transplantation for chronic myelocytic leukemia.
The New England journal of medicine 1990;322(25):1794-6.
1990: Herbert Tilg; Wolfgang Vogel; Walter Aulitzky; M Herold; Alfred Königsrainer; Raimund Margreiter; Christoph Huber
Evaluation of cytokines and cytokine-induced secondary messages in sera of patients after liver transplantation.
Transplantation 1990;49(6):1074-80.
1990: M Berger; Eveline U Irschick; E Fritsch; H Frommhold; D Schönitzer; J Wiegele; Georg Kemmler; Christoph Huber
Influence of local radiotherapy of breast cancer patients on the frequency of cytotoxic T lymphocyte precursor cells.
Immunobiology 1990;180(2-3):261-71.
1990: D Geissler; Guenther Gastl; Walter Aulitzky; Herbert Tilg; S Gaggl; Günther Konwalinka; Christoph Huber
Recombinant interferon-alpha-2C in chronic myelogenous leukaemia: relationship of sensitivity of committed haematopoietic precursor cells in vitro (BFU-E, CFU-GM, CFU-Meg) and clinical response.
Leukemia research 1990;14(7):629-36.
1990: Christoph Huber; Dietger Niederwieser
Role of cytokines and major histocompatibility complex antigens in graft-versus-host disease: in vitro studies using T-cell lines and keratinocytes or hemopoietic targets.
Haematology and blood transfusion 1990;33():652-4.
1989: Eveline U Irschick; K Miller; M Berger; Diether Schönitzer; J Koller; H Wagner; Wolfgang Göttinger; Christoph Huber
Studies of the mechanism of tolerance induced by short-term immunosuppression with cyclosporine in high-risk corneal allograft recipients. I. Analysis of CTL precursor frequencies.
Transplantation 1989;48(6):986-90.
1989: Walter Aulitzky; Guenther Gastl; W E Aulitzky; M Herold; J Kemmler; B Mull; J Frick; Christoph Huber
Successful treatment of metastatic renal cell carcinoma with a biologically active dose of recombinant interferon-gamma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1989;7(12):1875-84.
1989: Wolfgang Hinterberger; G Adolf; P Bettelheim; Klaus Geissler; Christoph Huber; E Irschick; Peter Kalhs; U Köller; Klaus Lechner; B Meister
Lymphokine overproduction in severe aplastic anemia is not related to blood transfusions.
Blood 1989;74(8):2713-7.
1989: Christian Marth; R Mull; Guenther Gastl; M Herold; E Steiner; Guenter Daxenbichler; H Hetzel; R Flener; Christoph Huber; Otto Dapunt
[The intraperitoneal installation of gamma interferon for the treatment of refractory ovarian carcinoma].
Geburtshilfe und Frauenheilkunde 1989;49(11):987-91.
1989: Herbert Tilg; Wolfgang Vogel; Walter Aulitzky; Diether Schönitzer; Raimund Margreiter; Otto Dietze; G Judmaier; H Wachter; Christoph Huber
Neopterin excretion after liver transplantation and its value in differential diagnosis of complications.
Transplantation 1989;48(4):594-9.
1989: Walter E Aulitzky; W Aulitzky; Guenther Gastl; B Lanske; J Reitter; J Frick; H Tilg; M Berger; M Herold; Christoph Huber
Acute effects of single doses of recombinant interferon-gamma on blood cell counts and lymphocyte subsets in patients with advanced renal cell cancer.
Journal of interferon research 1989;9(4):425-33.
1989: Josef Thaler; H Denz; O Dietze; Guenther Gastl; A D Ho; C Gattringer; richard greil; Monika Lechleitner; Christoph Huber; Heinz Huber
Immunohistological assessment of bone marrow biopsies from patients with hairy cell leukemia: changes following treatment with alpha-2-interferon and deoxycoformycin.
Leukemia research 1989;13(5):377-83.
1989: Christoph Huber; Walter Aulitzky
Clinical signs of immunodeficiency.
Current problems in dermatology 1989;18():42-9.
1989: Christoph Huber; M Herold
The importance of patient monitoring in clinical cytokine trials: use of serum markers to define biologically active doses.
Cancer surveys 1989;8(4):809-15.
1988: K Greil; C Gattringer; B Fasching; J Cleveland; Josef Thaler; T Radaskiewicz; Guenther Gastl; Christoph Huber; U Rapp; Heinz Huber
abl oncogene expression in non-Hodgkin lymphomas: correlation to histological differentiation and clinical status.
International journal of cancer. Journal international du cancer 1988;42(4):529-38.
1988: D Geissler; Dietger Niederwieser; Walter Aulitzky; H Tilg; Kurt Grünewald; Christoph Huber; Günther Konwalinka
Serum colony stimulating factors in patients undergoing bone marrow transplantation: enhancing effect of recombinant human GM-CSF.
Behring Institute Mitteilungen 1988;(83):289-300.
1988: Wolfgang Hinterberger; G Adolf; G Aichinger; R Dudczak; Klaus Geissler; Paul Höcker; Christoph Huber; Peter Kalhs; Walter Knapp; U Köller
Further evidence for lymphokine overproduction in severe aplastic anemia.
Blood 1988;72(1):266-72.
1988: Walter Aulitzky; Herbert Tilg; Dietger Niederwieser; Georg Riccabona; L Obendorf; Raimund Margreiter; Walter Pfaller; Christoph Huber
Comparison of serum neopterin levels and urinary neopterin excretion in renal allograft recipients.
Clinical nephrology 1988;29(5):248-52.
1988: Guenther Gastl; Christoph Huber
The biology of interferon actions.
Blut 1988;56(5):193-9.
1988: Dietger Niederwieser; J Auböck; J Troppmair; M Herold; Gerold Schuler; G Boeck; J Lotz; Peter Fritsch; Christoph Huber
IFN-mediated induction of MHC antigen expression on human keratinocytes and its influence on in vitro alloimmune responses.
Journal of immunology (Baltimore, Md. : 1950) 1988;140(8):2556-64.
1988: J Auböck; Eveline U Irschick; Nikolaus Romani; P Kompatscher; Reinhard Höpfl; M Herold; Gerold Schuler; M Bauer; Christoph Huber; Peter Fritsch
Rejection, after a slightly prolonged survival time, of Langerhans cell-free allogeneic cultured epidermis used for wound coverage in humans.
Transplantation 1988;45(4):730-7.
1988: K Nachbaur; J Troppmair; B Kotlan; P König; Walter Aulitzky; P Bieling; Christoph Huber
Cytokines in the control of beta-2 microglobulin release. II. In vivo studies with recombinant interferons and antigens.
Immunobiology 1988;177(1):66-75.
1988: K Nachbaur; J Troppmair; P Bieling; B Kotlan; P König; Christoph Huber
Cytokines in the control of beta-2 microglobulin release. I. In vitro studies on various haemopoietic cells.
Immunobiology 1988;177(1):55-65.
1988: K Miller; Christoph Huber; Dietger Niederwieser; Wolfgang Göttinger
Successful engraftment of high-risk corneal allografts with short-term immunosuppression with cyclosporine.
Transplantation 1988;45(3):651-3.
1988: J Troppmair; J Auböck; Dietger Niederwieser; D Schönitzer; Christoph Huber
Interferons (IFNs) and tumor necrosis factors (TNFs) in T cell-mediated immune responses against alloantigens. I. Influence on the activation of resting and antigen-primed T cells.
Immunobiology 1988;176(3):236-54.
1988: Christoph Huber; Eveline U Irschick
Cytokines in the regulation of allograft rejection.
Bibliotheca cardiologica 1988;(43):103-10.
1987: W Aulitzky; Guenther Gastl; Walter E Aulitzky; K Nachbaur; B Lanske; G Kemmler; R Flener; J Frick; Christoph Huber
Interferon-gamma for the treatment of metastatic renal cancer: dose-dependent stimulation and downregulation of beta-2 microglobulin and neopterin responses.
Immunobiology 1987;176(1-2):85-95.
1987: D Schönitzer; Herbert Tilg; Dietger Niederwieser; Walter Aulitzky; Raimund Margreiter; Christoph Huber
ABO-incompatible renal transplantation: report of two transplants from AB donors to A recipients.
Transplantation proceedings 1987;19(6):4547-8.
1987: Christoph Huber; Walter Aulitzky; Herbert Tilg; I von Lüttichau; J Troppmair; K Nachbauer; Guenther Gastl
Studies on the optimal dose and the mode of action of alpha-interferon in the treatment of hairy cell leukemia.
Leukemia 1987;1(4):355-7.
1987: W R Herzog; B Zanker; Eveline U Irschick; Christoph Huber; H E Franz; H Wagner; Dieter Kabelitz
Selective reduction of donor-specific cytotoxic T lymphocyte precursors in patients with a well-functioning kidney allograft.
Transplantation 1987;43(3):384-9.
1987: Dietger Niederwieser; Walter Aulitzky; H Frommhold; D Schönitzer; M Url; F Allerberger; J Wiegele; A Gratwohl; H Braunsteiner; Christoph Huber
[Experience using bone marrow transplantation in the treatment of hematologic neoplasms and solid tumors].
Wiener klinische Wochenschrift 1987;99(2):49-53.
1986: Guenther Gastl; Walter Aulitzky; Herbert Tilg; K Nachbaur; J Troppmair; R Flener; Christoph Huber
A biological approach to optimize interferon treatment in hairy cell leukemia.
Immunobiology 1986;172(3-5):262-8.
1986: Eveline U Irschick; R Margreiter; P König; M Spielberger; D Schönitzer; A Lochs; H Wagner; K Wonigeit; Christoph Huber
Exogenous IL2 partially reverts CML non-reactivity acquired during prophylactic immunosuppression with cyclosporin A of human allograft recipients.
Immunobiology 1986;172(1-2):21-32.
1986: W Woloszczuk; J Troppmair; E Leiter; R Flener; M Schwarz; J Kovarik; E Pohanka; R Margreiter; Christoph Huber
Relationship of interferon-gamma and neopterin levels during stimulation with alloantigens in vivo and in vitro.
Transplantation 1986;41(6):716-9.
1986: Guenther Gastl; Walter Aulitzky; E Leiter; R Flener; Christoph Huber
Alpha-interferon induces remission in hairy cell leukemia without enhancement of natural killing.
Blut 1986;52(5):273-9.
1986: Walter Aulitzky; Guenther Gastl; Herbert Tilg; J Troppmair; E Leiter; D Geissler; R Flener; Christoph Huber
[Interferon-alpha in the treatment of hematologic neoplasms].
Wiener medizinische Wochenschrift (1946) 1986;136(7-8):172-81.
1986: Guenther Gastl; H Rumpold; D Kraft; C Gattringer; G Schuler; R Margreiter; F Schmalzl; Christoph Huber
Abnormal expansions of granular lymphocytes: reactive lymphocytosis or chronic leukemia? Case report and literature review.
Blut 1986;52(2):73-89.
1986: Christoph Huber; E Irschik; E Leiter; H Binz; Dietger Niederwieser; M Spielberger; H Kathrein; D Schönitzer; R Margreiter
Use of donor-specific T-cell lines for monitoring of human allograft recipients. I. Demonstration of IgG binding to autologous TCL.
Experimental cell biology 1986;54(1):16-24.
1986: G Wieser; J Wiegele; J Troppmair; E Leiter; U Ganzinger; R Margreiter; Christoph Huber
Influence of ethylene-2,2'-bis (dithio)bis(ethanol) on certain human in vitro and in vivo lymphocyte functions.
International journal of immunopharmacology 1986;8(8):831-40.
1985: Guenther Gastl; Christian Marth; E Leiter; C Gattringer; I Mayer; Guenter Daxenbichler; R Flener; Christoph Huber
Effects of human recombinant alpha 2 arg-interferon and gamma-interferon on human breast cancer cell lines: dissociation of antiproliferative activity and induction of HLA-DR antigen expression.
Cancer research 1985;45(7):2957-61.
1985: Guenther Gastl; H Denz; C Abbrederis; Heinz Huber; J Troppmair; J Wiegele; Dietger Niederwieser; R Flener; Christoph Huber
Treatment with low dose human recombinant interferon-alpha-2-ARG induces complete remission in patients with hairy cell leukemia.
Onkologie 1985;8(3):143-4.
1985: E Leiter; R Pfister; D Lutz; G Michlmayr; H Gadner; C Gattringer; F Schmalzl; H Braunsteiner; Christoph Huber
Surface glycoproteins (S-GP) on normal and malignant human leukocytes.
Blut 1985;50(3):157-68.
1985: Eveline U Irschick; Dietger Niederwieser; A Lochs; M Spielberger; C Gattringer; R Margreiter; Christoph Huber
Follow-up studies on proliferative T cell responses in cadaveric kidney graft recipients under combined immunosuppressive treatment with cyclosporine and prednisone.
Immunobiology 1985;169(2):128-38.
1985: J Auböck; Dietger Niederwieser; N Romani; Peter Fritsch; Christoph Huber
Human interferon-gamma induces expression of HLA-DR on keratinocytes and melanocytes.
Archives of dermatological research 1985;277(4):270-5.
1984: R Margreiter; A Lang; P Koenig; H Kathrein; M Spielberger; E Steiner; Christoph Huber
Cyclosporine in the treatment of acute allograft rejection refractory to high-dose methylprednisolone: results of a prospectively randomized trial.
Transplantation proceedings 1984;16(5):1202-4.
1984: E Steiner; F Aigner; H Kathrein; Christoph Huber; R Margreiter
[Value of preventive immunoglobulin administration in cadaveric kidney transplantation].
Wiener klinische Wochenschrift 1984;96(7):264-6.
1983: Guenther Gastl; F Schmalzl; D Huhn; C Gattringer; Christoph Huber
Large granular lymphocytes: morphological and functional properties. I. Results in normals.
Blut 1983;46(6):297-310.
1983: E Leiter; D Lutz; G Michlmayr; H Gadner; Christoph Huber
[Surface glycoproteins of normal and malignant leukocytes].
Wiener klinische Wochenschrift 1983;95(5):149-53.